PPD to present at second annual World Pharma Trials
(Wilmington, N.C.) PPD, Inc. (Nasdaq: PPDI) today announced Simon Britton, vice president of clinical development, Asia Pacific, is a guest speaker at the World Pharma Trials 2010 conference in Singapore. His presentation will address the effectiveness of Asia’s people, infrastructure and CROs in supporting the region’s growing drug development activities. PPD is a silver sponsor of this year’s event.
Britton will join a panel of experts in analyzing supply versus demand of investigator sites, clinical trial experts, qualified partners and other drug development resources in Asia. The panel will also evaluate how well Asia is handling the increase of global biopharmaceutical companies moving their drug development programs into the region and innovative strategies to access untapped emerging countries. The presentation is Wednesday, March 17, at 11:55 a.m. UTC.
Britton provides strategic leadership for PPD’s clinical research business throughout Asia Pacific and plays an integral role in the company’s growth and development in the region.
PPD is one of the largest CROs in Asia Pacific with more than 1,400 employees and offices in 10 countries. In 2009, PPD acquired Excel PharmaStudies and BioDuro, strengthening its full range of drug discovery and development services and ability to provide scientific and technical expertise, global reach and a local understanding of clinical research in the region.
World Pharma Trials Asia brings together leaders from biopharmaceutical companies and CROs to explore a broad range of offshoring and outsourcing topics. The Asia drug development market is doubling in size each year as more global pharmaceutical companies conduct their clinical research programs in this growing region.
PPD is a leading global contract research organization, celebrating 25 years of providing discovery and development services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 40 countries and more than 10,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and commitment to quality to help clients and partners maximize returns on R&D investments that accelerate the delivery of safe, effective therapeutics. For more information, visit www.ppdi.com.

